Drug Type Small molecule drug |
Synonyms PF 06940434 |
Target |
Mechanism CD51 antagonists(Integrin alpha-V antagonists), αvβ8 inhibitors(Integrin αvβ8 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bile Duct Neoplasms | Phase 1 | US | 13 Nov 2019 | |
Bile Duct Neoplasms | Phase 1 | AU | 13 Nov 2019 | |
Bile Duct Neoplasms | Phase 1 | SK | 13 Nov 2019 | |
Bile Duct Neoplasms | Phase 1 | KR | 13 Nov 2019 | |
Bile Duct Neoplasms | Phase 1 | TW | 13 Nov 2019 | |
Endometrial Carcinoma | Phase 1 | US | 13 Nov 2019 | |
Endometrial Carcinoma | Phase 1 | AU | 13 Nov 2019 | |
Endometrial Carcinoma | Phase 1 | SK | 13 Nov 2019 | |
Endometrial Carcinoma | Phase 1 | KR | 13 Nov 2019 | |
Endometrial Carcinoma | Phase 1 | TW | 13 Nov 2019 |